Wounds and Injuries Clinical Trial
Official title:
A Randomized, Open-label, Multi-center, Controlled Clinical Study to Compare MAR-CUTIS With Dermabond Advanced in Closure of Surgical Incisions and Lacerations up to 15 Centimeters
Verified date | July 2020 |
Source | Grünenthal GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a randomized, open-label, multicenter, comparator-controlled clinical study to compare MAR-CUTIS with Dermabond Advanced in closure of surgical incisions and lacerations less than or equal to (<=)15 centimeter (cm). Eligible participants were randomized 2:1 to MAR-CUTIS or Dermabond Advanced.
Status | Terminated |
Enrollment | 107 |
Est. completion date | September 4, 2019 |
Est. primary completion date | July 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility |
Inclusion Criteria: For participants with surgical incisions: 1. Participants underwent closure of surgical incision 6 to 15 centimeters (cms) following laparotomy, abdominal hysterectomy, or laparoscopic intervention. For participants with lacerations: 2. Participants requiring closure of a laceration on face (avoiding the immediate area around the eye) or extremities. In participants with multiple lacerations, one was selected as the target wound (i.e., greatest length and meets the study entry criteria). For all participants: 3. Participant had given written informed consent/assent to participate. 4. Male and female participants at least 2 years of age and body weight 10 kilogram (kg) or greater. 5. Participants willing and capable of following instructions for wound care provided by the investigator and agreeing to return for all treatment control visits specified in this clinical study. Exclusion Criteria: For participants with lacerations: 1. Wounds on mucosal surfaces or across mucocutaneous junctions (e.g., oral cavity, lips, eyes). 2. Wounds which might be regularly exposed to body fluids or with dense natural hair (e.g., scalp); wounds on ears. 3. Wounds on palms and feet. 4. Animal or human bites. 5. Lacerations that were heavily contaminated. 6. Punctured or crushed wounds. 7. Participants with lacerations having wound treatment more than 6 hours after the trauma. For all participants: 8. Participants requiring suturing with sutures greater than 5 mm thickness. 9. Participants with documented skin disease or skin conditions (e.g., excessive hair at the site of surgery, scar tissue, wound, tattoo, coloration, or pre-existing open sores at the site of surgery that would interfere with the application of Investigational Medical Device or the skin assessment, as judged by the investigator). 10. Participant with any factors that might had an adverse effect on wound healing (e.g., previous history of keloid formation or hypertrophy [as well in the family]), history of immunosuppression, chronic systemic infection, or poor general health. 11. Participants with known blood clotting disorders. 12. Participants receiving steroids, immunosuppressants, chemotherapy, or anticoagulants. 13. Participants having known or suspected allergy or sensitivity to polyurethane, cyanoacrylates, formaldehyde, tapes or adhesives, or benzalkonium chloride. 14. Participant participating in any current clinical study with a non-CE ("Conformitee Europeene") marked device or investigational product. 15. Participant who was pregnant or breastfeeding. 16. Participant with history of a significant dermatologic disease or condition, such as atopic dermatitis, psoriasis, lichen ruber planus, vitiligo or conditions known to alter the skin appearance or physiologic response (e.g., decompensated diabetes mellitus, porphyria) that involves the investigative site. Removal of Participants From Therapy or Assessments: Only participants that were withdrawn from the study due to product failure at the time of application were replaced. Participants might stop the study for any of the following reasons: 1. Participant request. 2. Use of non-permitted concurrent therapy. 3. Lost to follow-up (considered lost to follow-up only before Day 10). 4. Occurrence of adverse events not compatible with the continuation of participant participation in the study, in the investigator's opinion, or unacceptable to the participant to continue. - Investigator request. - Inter-current illness. |
Country | Name | City | State |
---|---|---|---|
France | 004 - CHU Amiens-Picardie | Amiens | |
France | 005 - Hôpital Privé Paul d'Egine | Champigny-sur-Marne | |
Germany | 010 - Charité Berlin | Berlin | |
Germany | 006 - Universitätsklinikum Heidelberg | Heidelberg | |
Germany | 009 - Klinikum Magdeburg | Magdeburg | |
Spain | 001 - Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | 022 - Hospital General Universitario Gregorio Maranon | Madrid | |
Spain | 003 - University Hospital Virgen del Rocío | Seville | |
United Kingdom | 019 - Barnsley Hospital | Barnsley | |
United Kingdom | 017 - Birmingham Children's Hospital | Birmingham | |
United Kingdom | 018 - Bristol Royal Hospital for Children | Bristol | |
United Kingdom | 021 - University Hospital of Wales | Cardiff | |
United Kingdom | 013 - The Princess Alexandra Hospital | Harlow | |
United Kingdom | 011 - Leeds Teaching Hospitals | Leeds | |
United Kingdom | 016 - St George's Hospital | London | |
United Kingdom | 014 - Queen Elizabeth the Queen Mother Hospital | Margate | |
United Kingdom | 020 - Royal Gwent Hospital | Newport | |
United Kingdom | 012 - Peterborough City Hospital | Peterborough | |
United Kingdom | 015 - Musgrove Park Hospital | Taunton |
Lead Sponsor | Collaborator |
---|---|
Grünenthal GmbH | Syneos Health |
France, Germany, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Total Dehiscence of Target Wound at Day 10 | Wound dehiscence involved the breaking open of the surgical incision along the suture. Number of participants with dehiscence (reported as "yes") and number of participants showing no dehiscence (reported as "No"). | At Day 10 | |
Primary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | A TEAE was defined as any adverse event (AE) that occured during the on-treatment-period (i.e. after the start of the application of the Investigational Medical Device (IMD) (Day 0) until the end-of-treatment visit [Month 3]).This included any events related to the procedures, the IMD, or the comparator. An SAE was any untoward medical occurrence or effect that: led to death, or led to serious deterioration in the health of the participant, that either resulted in: life-threatening illness or injury, or a permanent impairment of a body structure or a body function, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-threatening illness or injury or permanent, or impairment to a body structure or a body function. Or, led to fetal distress, fetal death, or a congenital abnormality or birth defect. | From Baseline (Day 0) up to Month 3 | |
Secondary | Number of Participants With Total Dehiscence of Target Wound at Month 1 | Wound dehiscence involved the breaking open of the surgical incision along the suture. | At Month 1 | |
Secondary | Number of Participant's Reporting Satisfaction With the Device Using Patient and Observer Scar Assessment Scale (POSAS) | The POSAS was a questionnaire that was developed to assess scar quality. It consisted of 2 separate 6-item scales (Patient Scale and Observer Scale), both of which were scored on a 10-point rating scale. In addition, each scale has an overall "opinion" with 1 being no pain, no itching, or normal skin and 10 being worst scar imaginable with pain and itching, where lower scores indicated better outcome. | At Month 1 and Month 3 | |
Secondary | Percentage of Participants With Wound Infections | The wound infection incidence was assessed at the scheduled visits diagnosed according to the Centers for Disease Control and Prevention (CDC) criteria for surgical site infection. Wound infection was assessed and the following symptoms were evaluated if infection was present: Presence of erythema Presence of edema Presence of pain at rest Presence of elevated temperature Percentage of participants with wound infections around target wound are reported. |
At Day 10, and Month 1 | |
Secondary | Investigator's Satisfaction With the Device Using Patient and Observer Scar Assessment Scale (POSAS) | The POSAS was a questionnaire that was developed to assess scar quality. Investigator were asked to rate the severity of participant's scar compared to normal skin. The overall "opinion" ranged from 1= no pain, no itching, or normal skin to 10 = worst scar imaginable with pain and itching, where lower scores indicated better outcome. | At Month 1 and Month 3 | |
Secondary | Investigator's Satisfaction With the Device Using Modified Hollander Cosmesis Scale | The investigator's satisfaction with the cosmetic outcome was assessed using the Modified Hollander Cosmesis Scale (mHCS). The mHCS consisted of 6 wound characteristics: Step-off borders, Contour irregularities, Target wound margin separation, Edge inversion, Excessive inflammation, Overall appearance. It was evaluated as "poor" or "good". Each of the characteristics was graded on a 0 (no/good) or 1 (yes/poor) point scale, where lower score indicated better outcome. Number of participants with different wound characteristics (poor and good) and participants with missing response are also reported. | At Day 10 and Month 1 | |
Secondary | Number of Participant Reporting Satisfaction With the Device Using a Product-Related Questionnaire | The questionnaire consisted of 5 yes/no questions that evaluated the participant's experience with the adhesive, 1 question that rated the effect of the closed wound on several daily activities (i.e., showering, getting dressed), 1 question that evaluated satisfaction with the wound closure, and visual analog scales which rate pain and scarring. | At Day 10 and Month 1 | |
Secondary | Number of Participants Reporting Satisfaction With the Device Evaluated by Investigator Using a Product-Related Questionnaire | The questionnaire consisted of 5 yes/no questions that assess the investigator's experience applying the adhesive (i.e., easy to use, fast, without complications), a visual analog scale that rates usability of the product from 1 (poor = very difficult to use) to 100 (excellent = very easy to use), and 1 question that evaluates satisfaction with the adhesive. | At Day 0 and Month 1 | |
Secondary | Investigator's Satisfaction With Ease of Use With the Device Using a Product-Related Questionnaire | The questionnaire consisted of 8 yes/no questions and 1 opinion question that evaluated the investigator's experience with use of the adhesive (i.e., instructions easy to understand, preparation of the syringe being easy and fast, glue hardening time). | At Month 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04554212 -
Blood Flow Restriction Training After Patellar INStability
|
N/A | |
Suspended |
NCT02932176 -
Machine Learning for Handheld Vascular Studies
|
||
Recruiting |
NCT04803253 -
Study of the Social and Professional Reintegration Improvements Using a Set of Solutions for Upper Limb Amputation
|
N/A | |
Completed |
NCT00116337 -
Spinal Cord Stimulation to Restore Cough
|
N/A | |
Completed |
NCT03463720 -
Outcome for Patients With War-Associated Extremity Wound Infection
|
N/A | |
Completed |
NCT03113253 -
TRANexamic Acid to Reduce Bleeding in BURN Surgery
|
Phase 4 | |
Not yet recruiting |
NCT05492903 -
COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
|
N/A | |
Terminated |
NCT02909231 -
One-year Patient Reported Outcomes Following Hospitalization for Trauma
|
N/A | |
Completed |
NCT02432456 -
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients
|
Phase 4 | |
Completed |
NCT02266771 -
Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice
|
N/A | |
Completed |
NCT02744144 -
Wound Bacterial Microbiota and Their Antibiotic Resistance
|
N/A | |
Completed |
NCT02394821 -
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
|
Phase 3 | |
Not yet recruiting |
NCT01665963 -
Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds
|
N/A | |
Completed |
NCT00151112 -
Comparison of Two Different Procedures for Plexus Anesthesia
|
N/A | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT04596124 -
Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze
|
N/A | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Terminated |
NCT04775316 -
Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
|
||
Enrolling by invitation |
NCT03312504 -
Implementing a School Prevention Program to Reduce Injuries Through Neuromuscular Training
|
N/A |